JB Pharma Q1 FY26 PAT up at 14% to Rs. 202 Cr

Jubilant Ingrevia Q1 FY26 YoY net profit jumps 54% to Rs. 75 Cr

Our specialty chemical businesses have continued to perform strongly, growing double digit YoY

Astec LifeSciences Q1 FY26 revenue up 30.3%

The company reported consolidated EBITDA loss of Rs. 10.5 crore in Q1 FY26 as compared to loss of Rs. 45.3 crore in the same period last year

Jagsonpal Pharmaceuticals Q1 FY26 revenue up 23.1%

Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution

Dr Reddy's Laboratories reports 2% rise in Q1 net profit to Rs. 1,418 Cr

Revenue increased 11.4 per cent to Rs. 8,545 crore

Syngene reports Q1 FY26 revenue higher at Rs. 875 Cr

Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%

Lonza reports 19% growth in sales in H1

Upgrades 2025 full-year CDMO sales and margin outlook

Aarti Drugs posts Q1 FY26 PAT higher at Rs. 54 Cr

During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D

SeQuent–Viyash merger receives stock exchange approvals; NCLT filing underway

QMS Medical Allied Services posts 134.36% jump in consolidated PAT in Q4 FY25

Operating income on consolidated basis increased by 38.10% at Rs 44.58 crore in Q4 FY25